Patents
Literature
4 results about "Plasmacytoid dendritic cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Plasmacytoid dendritic cells (pDCs) are a rare type of immune cell that are known to secrete large quantities of type 1 interferon (IFNs) in response to a viral infection. They circulate in the blood and are found in peripheral lymphoid organs. They develop from bone marrow hematopoietic stem cells and constitute < 0.4% of peripheral blood mononuclear cells (PBMC). Other than conducting antiviral mechanisms, pDCs are considered to be key in linking the innate and adaptive immune systems. However, pDCs are also responsible for participating in and exacerbating certain autoimmune diseases like lupus. pDCs are also the malignant cell that causes a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm.
BDCA2-targeted antibodies and their applications
The present invention discloses an anti-BDCA2 antibody and its antigen-binding fragment, a polynucleotide encoding the antibody and its antigen-binding fragment, and a pharmaceutical composition comprising the antibody and its antigen-binding fragment. Furthermore, the use of the anti-BDCA2 antibody and its antigen-binding fragment described in the present invention in the treatment of plasmacytoid dendritic cell (pDC) or type I interferon (type I IFN)-associated immune diseases is also disclosed.
Owner:インマージーン プライベート リミテッド
Noncompetitive receptor-targeted vaccine delivery to plasmacytoid dendritic cells
PendingUS20260183239A1Plasmacytoid dendritic cellVaccine delivery
Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Vaccines using macrophage suppression
PCT designated stageWO2026112381A1Antibody mimetics/scaffoldsViral antigen ingredientsDiseasePlasmacytoid dendritic cell
Provided herein are IL-10 variant sequences. In some embodiments, the IL-10 variants are immunosilent, and / or are capable of suppressing monocyte, macrophage, or pDC activity. Also disclosed herein are vaccines comprising the IL-10 variants, and methods of treatment for diseases and disorders that correspond with activating adaptive immunity.
Owner:RGT UNIV OF CALIFORNIA
Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof
PendingUS20260185048A1Plasmacytoid dendritic cellPlasma cell
The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.
Owner:ASGARD THERAPEUTICS AB